Article

POZ Domain Transcription Factor Kaiso is a Downstream Effector of STAT1 for Multiple Myeloma Cell Survival and is also essential for Anoikis Resistance of Metastatic Solid Tumors

2025-09-30

Abstract excerpt

Role of the transcription factor STAT1 in cancer cell survival has remained unclear. Here we document an oncogenic role for STAT1 in Multiple Myeloma (MM), wherein STAT1 regulates Kaiso expression, represses bmf and is essential for MM cell survival. Moreover, STAT1 is constitutively phosphorylated in MM cell lines and patient derived primary MM cells and STAT1-depletion resulted in reduced Kaiso levels. Importan...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dc2a7a8f-d0cd-57fb-8665-c2358e275e6c
DOI: 10.1101/2025.09.29.675399

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

POZ Domain Transcription Factor Kaiso is a Downstream Effector of STAT1 for Multiple Myeloma Cell Survival and is also essential for Anoikis Resistance of Metastatic Solid TumorsDOI 10.1101/2025.09.29.675399Read

c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myelomaSemantic proximity Read

Identification of biomarkers and candidate regulators for multiple myeloma under the knockout of AURKASemantic proximity Read

The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myelomaSemantic proximity Read

Elevated levels of Protein S in Multiple Myeloma bone marrow microenvironment regulate tumor progression and bone diseaseSemantic proximity Read

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myelomaSemantic proximity Read

Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma CellsSemantic proximity Read

The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma PathophysiologySemantic proximity Read

Selective Enhancer Gain-of-Function Deregulates MYC Expression in Multiple MyelomaSemantic proximity Read

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expressionSemantic proximity Read

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myelomaSemantic proximity Read

How to Reprogram Myeloma-Associated Macrophages: Target IKZF1.Semantic proximity Read

Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkBSemantic proximity Read